• Journal Article

Persistence and Compliance among US Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma

Citation

DaCosta Byfield, S., McPheeters, J., Burton, T., Nagar, S., & Hackshaw, M. I. (2015). Persistence and Compliance among US Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma. Journal of Managed Care Pharmacy, 21(6), 515 - 22.

Abstract